Newswise — SACRAMENTO – NeuroVision Imaging Inc. announced it has received an additional investment from the Alzheimer’s Drug Discovery Foundation (ADDF) – the foundation’s second round of funding to Neurovision this year – to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.
The ability to measure multiple dementia-related biomarkers in the blood and correlate them with disease status and prognosis could make diagnostic testing more practical, less invasive and less costly. Not only would this give researchers and clinicians a better understanding of disease progression, it could improve clinical trials and the search for new treatments by providing a relatively quick and easy way to accurately monitor patients’ responses to therapy.
“Our best…
